Entia Biosciences, Inc.
ERGO
Get informed when a big investor buys or sells
+ FollowMarket Cap$6.73K
Close$
Share Statistics
| Market cap | $6,732.00 |
|---|---|
| Enterprise Value | $976,683.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.05 |
| Beta | 3.27 |
| Outstanding Shares | 28,146,124 |
Return
| Return on Equity | 74.88% |
|---|---|
| Return on Assets | -335.35% |
| Return on Invested Capital | 79.03% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | -0.01 |
| Price to Sales | - |
| Price to Book Ratio | -0.0 |
| Enterprise Value to Revenue | 3.68 |
| Enterprise Value to EBIT | -0.74 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 1.07 |
| Debt to Equity | -0.53 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Entia Biosciences, Inc.
6 employees
CEO: Timothy A. Timmins Entia Biosciences, Inc. engages in the development, production, and distribution of dietary supplements, nutraceuticals, and medical food products in the United States. The company develops ErgoD2, a pharmaceutical grade organic compound...